Analysts predict that Ritter Pharmaceuticals Inc (NASDAQ:RTTR) will report earnings of ($0.84) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Ritter Pharmaceuticals’ earnings. The highest EPS estimate is ($0.72) and the lowest is ($0.95). Ritter Pharmaceuticals reported earnings per share of ($1.40) in the same quarter last year, which would suggest a positive year-over-year growth rate of 40%. The company is expected to issue its next earnings report on Tuesday, October 30th.

On average, analysts expect that Ritter Pharmaceuticals will report full-year earnings of ($2.97) per share for the current financial year, with EPS estimates ranging from ($3.30) to ($2.63). For the next financial year, analysts anticipate that the firm will report earnings of ($1.76) per share, with EPS estimates ranging from ($2.12) to ($1.40). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Ritter Pharmaceuticals.

Ritter Pharmaceuticals (NASDAQ:RTTR) last released its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.15).

A number of research firms have issued reports on RTTR. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Ritter Pharmaceuticals in a report on Wednesday, August 15th. ValuEngine upgraded shares of Ritter Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd. Finally, Zacks Investment Research upgraded shares of Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 1st.

In other Ritter Pharmaceuticals news, Director Matthew W. Foehr bought 19,751 shares of Ritter Pharmaceuticals stock in a transaction on Friday, August 17th. The shares were bought at an average cost of $2.04 per share, for a total transaction of $40,292.04. Following the acquisition, the director now directly owns 54,751 shares in the company, valued at $111,692.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 21.60% of the stock is owned by corporate insiders.

Ritter Pharmaceuticals stock traded down $0.04 during mid-day trading on Friday, reaching $1.68. 41,510 shares of the company’s stock were exchanged, compared to its average volume of 172,827. The firm has a market cap of $8.63 million, a PE ratio of -0.34 and a beta of 0.64. Ritter Pharmaceuticals has a twelve month low of $1.40 and a twelve month high of $4.15.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.

Featured Article: Understanding Average Daily Trade Volume

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.